Nolawit Tesfaye is an Endocrinology/Metabolic physician affiliated with University of Minnesota. OpenAlex indexes 8 publications with 310 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2450 Riverside Ave
Minneapolis, MN 554541450
Telephone
612-672-6000Provider last certified this registry record 10 Feb 2022.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
61.3%RANK Ligand Inhibitor58.5%Denosumab100%Part B, office-administered≥13 patientsBisphosphonates2.8%Risedronate Sodium100%Part D<11 patientsHormonal (systemic)
22.1%l-Thyroxine13.7%Levothyroxine Sodium95%Synthroid5%Part D<11 patientsThyroid Hormone Synthesis Inhibitor5.4%Methimazole100%Part D≥16 patients+ 2 more classes in this area
Metabolism & gastrointestinal
14.2%GLP-1 receptor agonist4.5%Ozempic60%Mounjaro22%Trulicity19%Part D<11 patientsInsulin Analog4.4%Humalog Kwikpen U-10032%Tresiba Flextouch U-10032%Lantus Solostar21%Novolog15%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Suboptimal osteoporosis screening rates persist in patients on long-term glucocorticoid therapy: current experience within an academic health system
Journal of Clinical & Translational Endocrinology
2026 - Naltrexone for treatment of impaired awareness of hypoglycemia in type 1 diabetes: A randomized clinical trial
Journal of Diabetes and its Complications
2015 - Hypoglycemia-Induced Increases in Thalamic Cerebral Blood Flow are Blunted in Subjects with Type 1 Diabetes and Hypoglycemia Unawareness
Journal of Cerebral Blood Flow & Metabolism
2012 - Brain Glycogen Content and Metabolism in Subjects with Type 1 Diabetes and Hypoglycemia Unawareness
Journal of Cerebral Blood Flow & Metabolism
2011
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Blazar, MD
University of Minnesota
Jay Cohn, MD
University of Minnesota
Julia Steinberger, MD
University of Minnesota
Charles Herzog, MD
University of Minnesota
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”